banner
Pwodwi kategori
Kontakte nou

Kontakte:Errol Zhou (Mesye.)

Tel: plis 86-551-65523315

Mobile/WhatsApp: plis 86 17705606359

QQ:196299583

Skype:lucytoday@hotmail.com

Imèl:sales@homesunshinepharma.com

Ajoute:1002, Huanmao Bilding, No.105, Mengcheng Wout, Hefei Vil, 230061, Lachin

APis ak Entemedye
Ledipasvir CAS 1256388-51-8

Ledipasvir CAS 1256388-51-8

CAS NON: 1256388-51-8
Fomil molekile: C49H54F2N8O6
Molekile Pwa: 889.00
EINECS NON: N / A
MDL NO: MFCD25976756

Pwodwi detay

Pwodwi Deskripsyon:

Non pwodwi: Ledipasvir CAS NON: 1256388-51-8

 

Sinonim:

GS-5885;

Methyl N-[(2S) -1-[(6S) -6-[5-[9,9-Difluoro-7-[2-[1S,2S,4 3-[(2S) -2-(methoxycarbonylamino) -3-methylbutanoyl]-3-azabicyclo [2.2. 2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-2-2 azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate;

 

Chimik & Pwopriyete fizik:

Aparans : blan pou poud blan

Assay: ≥99.0%

Dansite: 1.4 g / cm3

 

Ledipasvir (ansyen GS-5885) se yon dwog pou tretman epatit C ki te devlope pa Gilead Syans. Apre ou fin ranpli ese klinik III, sou fevriye 10, 2014 Gilead te depoze pou apwobasyon Ameriken nan yon ledipasvir / sofosbuvir fiks-doz konbinezon grenn pou genotype 1 epatit C. Konbinezon ledipasvir / sofosbuvir a se yon ajan antiviral direk ki entefere ak replikasyon HCV epi yo ka itilize pou trete pasyan ki gen janotypes 1a oswa 1b san PEG-enteferans oswa ribari.

Ledipasvir se yon inibitor nan epatit C viris NS5A pwoteyin.

Done prezante nan konferans 20th sou Retroviruses ak Opotinis Enfeksyon nan mwa mas 2013 te montre ke yon rejim trip nan inibitor analog nucleotide a sofosbuvir, ledipasvir, ak ribavin pwodwi yon 12-semen pos-tretman soutni repons virolojik (SVR12) pousantaj de 100% pou tou de tretman-nave pasyan yo ak anvan ki pa sekouris ak HCV genotype 1. Se kofomasyon nan sofosbuvir / ledipaspas yo te teste ak ak san ribavin. Nan mwa fevriye 2014 Galarad te ranpli pou Manje Etazini ak Administrasyon Dwog (FDA) apwobasyon ledipasvir / tretman oral sofosbuvir, san entefewon ak ribavin.

Sou Oktob 10, 2014 FDA a apwouve konbinezon ledipasvir / sofosbuvir yo rele Harvoni.

 

 

Si ou enterese nan pwodwi nou yo oswa ou gen nenpot kesyon, tanpri santi yo lib yo kontakte nou!

 

 

Pwodwi anba patant yo ofri pou R & D rezon selman. Sepandan, denye responsablite a bay manti selman ak achte a.

 

 

 


Baj popilè: ledipasvir cas 125638-51-8, manifaktire, founise, faktori, achte, nan stock

Voye rechèch